Literature DB >> 22177547

Intracranial deep white matter lesions (DWLs) are associated with chronic kidney disease (CKD) and cognitive impairment: a 5-year follow-up magnetic resonance imaging (MRI) study.

N Kuriyama1, T Mizuno, Y Ohshima, K Yamada, E Ozaki, M Shigeta, S Mitani, M Kondo, S Matsumoto, K Takeda, M Nakagawa, Y Watanabe.   

Abstract

Stroke incidence and cognitive decline are related to progression of arteriosclerosis in intracranial DWLs. However, the relationships between DWLs and factors associated with their progression, including CKD, have not been fully elucidated using longitudinal MRI. Of 291 individuals (184 males, 107 females; age 66.9 ± 6.1 years) who had voluntarily participated in a hospital-based health check-up and underwent repeated brain MRI scans in 2003 and 2008, 273 were evaluated in this study. The DWL group included those having DWL without progression, and the DWL progression (DWLP) group included those having an increase in grade number according to the Fazekas classification. Unimpaired age-matched subjects with no brain MRI abnormalities constituted Group C. The Mini-Mental State Examination (MMSE) and verbal fluency tasks were used for objective cognitive evaluations according to the MR evaluation schedule in 2008. Associations between DWLs and vascular risk factors were examined. DWLP occurred in 9.2% of subjects. Compared to Group C subjects, DWL and DWLP group subjects had high odds ratios (ORs) for hypertension (HT) (2.23 and 2.92, respectively) and CKD (1.40 and 2.41, respectively). After adjustment for potential confounders, the ORs of CKD for DWLs remained significant (1.13 and 1.43, p<0.05). DWLs and DWLP were associated with low cognitive scale scores and increased CKD. In conclusion, CKD was associated with DWLs and DWLP as an independent risk factor and a lower level of cognitive function 5 years after CKD was identified. Successful CKD therapy may be expected to prevent DWLP.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22177547     DOI: 10.1016/j.archger.2011.11.009

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  12 in total

Review 1.  Aging and chronic kidney disease: the impact on physical function and cognition.

Authors:  Shuchi Anand; Kirsten L Johansen; Manjula Kurella Tamura
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-08-02       Impact factor: 6.053

Review 2.  The assessment of cognitive function in older adult patients with chronic kidney disease: an integrative review.

Authors:  Mary Hannan; Alana Steffen; Lauretta Quinn; Eileen G Collins; Shane A Phillips; Ulf G Bronas
Journal:  J Nephrol       Date:  2018-05-25       Impact factor: 3.902

3.  Associations of Early Kidney Disease With Brain Magnetic Resonance Imaging and Cognitive Function in African Americans With Type 2 Diabetes Mellitus.

Authors:  Barry I Freedman; Kaycee M Sink; Christina E Hugenschmidt; Timothy M Hughes; Jeff D Williamson; Christopher T Whitlow; Nicholette D Palmer; Michael E Miller; Laura C Lovato; Jianzhao Xu; S Carrie Smith; Lenore J Launer; Joshua I Barzilay; Robert M Cohen; Mark D Sullivan; R Nick Bryan; Benjamin C Wagner; Donald W Bowden; Joseph A Maldjian; Jasmin Divers
Journal:  Am J Kidney Dis       Date:  2017-06-23       Impact factor: 8.860

4.  Association Between White Matter Hyperintensities and Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Cun-Sheng Wei; Cai-Yun Yan; Xiao-Rong Yu; Lin Wang; Rui Zhang; Jun-Ying Jiang; Qi Dai; Jun-Rong Li; Xue Mei Chen
Journal:  Front Med (Lausanne)       Date:  2022-05-03

5.  Cognitive and kidney function: results from a British birth cohort reaching retirement age.

Authors:  Richard J Silverwood; Marcus Richards; Mary Pierce; Rebecca Hardy; Naveed Sattar; Charles Ferro; Caroline Savage; Diana Kuh; Dorothea Nitsch
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

6.  Oral Cnm-positive Streptococcus Mutans Expressing Collagen Binding Activity is a Risk Factor for Cerebral Microbleeds and Cognitive Impairment.

Authors:  Isao Watanabe; Nagato Kuriyama; Fumitaro Miyatani; Ryota Nomura; Shuhei Naka; Kazuhiko Nakano; Masafumi Ihara; Komei Iwai; Daisuke Matsui; Etsuko Ozaki; Teruhide Koyama; Masaru Nishigaki; Toshiro Yamamoto; Aiko Tamura; Toshiki Mizuno; Kentaro Akazawa; Akihiro Takada; Kazuo Takeda; Kei Yamada; Masanori Nakagawa; Tokutaro Tanaka; Narisato Kanamura; Robert P Friedland; Yoshiyuki Watanabe
Journal:  Sci Rep       Date:  2016-12-09       Impact factor: 4.379

7.  Serum albumin to globulin ratio is related to cognitive decline via reflection of homeostasis: a nested case-control study.

Authors:  Teruhide Koyama; Nagato Kuriyama; Etsuko Ozaki; Daisuke Matsui; Isao Watanabe; Fumitaro Miyatani; Masaki Kondo; Aiko Tamura; Takashi Kasai; Yoichi Ohshima; Tomokatsu Yoshida; Takahiko Tokuda; Ikuko Mizuta; Shigeto Mizuno; Kei Yamada; Kazuo Takeda; Sanae Matsumoto; Masanori Nakagawa; Toshiki Mizuno; Yoshiyuki Watanabe
Journal:  BMC Neurol       Date:  2016-12-08       Impact factor: 2.474

8.  Proceedings From the Symposium on Kidney Disease in Older People: Royal Society of Medicine, London, January 19, 2017.

Authors:  Aza Abdulla; Pandora N Wright; Louise E Ross; Hugh Gallagher; Osasuyi Iyasere; Nan Ma; Carol Bartholomew; Karen Lowton; Edwina A Brown
Journal:  Gerontol Geriatr Med       Date:  2017-12-07

9.  Malnutrition-inflammation is a risk factor for cerebral small vessel diseases and cognitive decline in peritoneal dialysis patients: a cross-sectional observational study.

Authors:  Ke Zheng; Haiyun Wang; Bo Hou; Hui You; Jing Yuan; Kai Luo; Limeng Chen; Mingxi Li; Qun Xu; Yicheng Zhu; Liying Cui; Sagar Uday Nigwekar; Feng Feng; Xuemei Li
Journal:  BMC Nephrol       Date:  2017-12-20       Impact factor: 2.388

10.  Validation of the R2CHADS2 and CHADS2 Scores for Predicting Post-stroke Cognitive Impairment.

Authors:  Kazuo Washida; Hisatomo Kowa; Hirotoshi Hamaguchi; Fumio Kanda; Tatsushi Toda
Journal:  Intern Med       Date:  2017-09-15       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.